CareDx Inc. (CDNA) shares reached a 52-week high of $49.77 on Tuesday, up from $49.69 in earlier trading, after the company reported second-quarter 2026 earnings and revenue that surpassed Wall Street expectations.
The diagnostics provider posted adjusted earnings per share of $0.37, exceeding the analyst consensus of $0.23. Total revenue climbed 52% year-over-year to $132 million, while testing revenue rose 61% to $99.9 million. Both figures topped forecasts of $113.82 million and $101.5 million, respectively. CareDx also raised its full-year outlook in response to the stronger-than-expected performance.
The company’s market capitalization stands at $2.57 billion. H.C. Wainwright maintained a Neutral rating on CareDx with a $46 price target, while InvestingPro’s Fair Value analysis flagged the stock as overvalued. CareDx’s Piotroski Score of 9—considered perfect—reflects exceptional financial strength, and its PEG ratio of 0.2 remains below the broader market average. Year-to-date, the stock has gained 283.22%.
CareDx’s second-quarter results follow a period of rapid growth, driven by increased demand for its diagnostic testing services. The company’s ability to exceed revenue and earnings estimates has reinforced investor confidence, pushing shares to their highest level in 12 months.
